These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 18538830)

  • 21. Safety profile of abatacept in rheumatoid arthritis: a review.
    Khraishi M; Russell A; Olszynski WP
    Clin Ther; 2010 Oct; 32(11):1855-70. PubMed ID: 21095481
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An index of only patient-reported outcome measures, routine assessment of patient index data 3 (RAPID3), in two abatacept clinical trials: similar results to disease activity score (DAS28) and other RAPID indices that include physician-reported measures.
    Pincus T; Bergman MJ; Yazici Y; Hines P; Raghupathi K; Maclean R
    Rheumatology (Oxford); 2008 Mar; 47(3):345-9. PubMed ID: 18238788
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the 'Orencia and Rheumatoid Arthritis' registry.
    Gottenberg JE; Ravaud P; Cantagrel A; Combe B; Flipo RM; Schaeverbeke T; Houvenagel E; Gaudin P; Loeuille D; Rist S; Dougados M; Sibilia J; Le Loët X; Marcelli C; Bardin T; Pane I; Baron G; Mariette X
    Ann Rheum Dis; 2012 Nov; 71(11):1815-9. PubMed ID: 22615458
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Abatacept in the treatment of rheumatoid arthritis.
    Todd DJ; Costenbader KH; Weinblatt ME
    Int J Clin Pract; 2007 Mar; 61(3):494-500. PubMed ID: 17313619
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to tumor necrosis factor-alpha antagonists.
    Vera-Llonch M; Massarotti E; Wolfe F; Shadick N; Westhovens R; Sofrygin O; Maclean R; Li T; Oster G
    J Rheumatol; 2008 Sep; 35(9):1745-53. PubMed ID: 18634164
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Indirect treatment comparison of abatacept with methotrexate versus other biologic agents for active rheumatoid arthritis despite methotrexate therapy in the United kingdom.
    Guyot P; Taylor PC; Christensen R; Pericleous L; Drost P; Eijgelshoven I; Bergman G; Lebmeier M
    J Rheumatol; 2012 Jun; 39(6):1198-206. PubMed ID: 22505698
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of abatacept for moderate-to-severe rheumatoid arthritis.
    Tsao NW; Shojania K; Marra CA
    Expert Rev Pharmacoecon Outcomes Res; 2014 Feb; 14(1):9-18. PubMed ID: 24325566
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Responsiveness of patient reported outcomes including fatigue, sleep quality, activity limitation, and quality of life following treatment with abatacept for rheumatoid arthritis.
    Wells G; Li T; Maxwell L; Maclean R; Tugwell P
    Ann Rheum Dis; 2008 Feb; 67(2):260-5. PubMed ID: 17846044
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Abatacept: a biologic immune modulator for rheumatoid arthritis.
    Papagoras C; Drosos AA
    Expert Opin Biol Ther; 2011 Aug; 11(8):1113-29. PubMed ID: 21649536
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial.
    Weinblatt M; Schiff M; Goldman A; Kremer J; Luggen M; Li T; Chen D; Becker JC
    Ann Rheum Dis; 2007 Feb; 66(2):228-34. PubMed ID: 16935912
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial.
    Kremer JM; Dougados M; Emery P; Durez P; Sibilia J; Shergy W; Steinfeld S; Tindall E; Becker JC; Li T; Nuamah IF; Aranda R; Moreland LW
    Arthritis Rheum; 2005 Aug; 52(8):2263-71. PubMed ID: 16052582
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Abatacept].
    Nakamura T; Matsubara T
    Nihon Rinsho; 2013 Jul; 71(7):1232-7. PubMed ID: 23961672
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Effect of CTLA4-Ig on radiographic outcome of patients with rheumatoid arthritis].
    Harigai M
    Clin Calcium; 2007 Apr; 17(4):577-84. PubMed ID: 17404488
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Psoriasiform lesions appearing in three patients with rheumatoid arthritis during therapeutic administration of abatacept, a selective inhibitor of T-cell costimulation.
    Konsta M; Rallis E; Karameris A; Stratigos A; Sfikakis PP; Iliopoulos A
    J Eur Acad Dermatol Venereol; 2012 Feb; 26(2):257-8. PubMed ID: 22280512
    [No Abstract]   [Full Text] [Related]  

  • 35. Quality of life in patients with rheumatoid arthritis: does abatacept make a difference?
    Michaud K; Bombardier C; Emery P
    Clin Exp Rheumatol; 2007; 25(5 Suppl 46):S35-45. PubMed ID: 17977487
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of immunogenicity of the T cell costimulation modulator abatacept in patients treated for rheumatoid arthritis.
    Haggerty HG; Abbott MA; Reilly TP; DeVona DA; Gleason CR; Tay L; Dodge R; Aranda R
    J Rheumatol; 2007 Dec; 34(12):2365-73. PubMed ID: 18050376
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proposed severity and response criteria for Routine Assessment of Patient Index Data (RAPID3): results for categories of disease activity and response criteria in abatacept clinical trials.
    Pincus T; Hines P; Bergman MJ; Yazici Y; Rosenblatt LC; MacLean R
    J Rheumatol; 2011 Dec; 38(12):2565-71. PubMed ID: 22089467
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is abatacept an effective treatment for patients with RA who do not respond to other anti-TNF treatments?
    Taylor PC
    Nat Clin Pract Rheumatol; 2006 Mar; 2(3):128-9. PubMed ID: 16932670
    [No Abstract]   [Full Text] [Related]  

  • 39. Rheumatoid arthritis: beyond tumor necrosis factor-alpha antagonists, B cell depletion, and T cell blockade.
    Manadan AM; Block JA
    Am J Ther; 2008; 15(1):53-8. PubMed ID: 18223354
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Abatacept: a T-cell co-stimulation modulator for the treatment of rheumatoid arthritis.
    Ostör AJ
    Clin Rheumatol; 2008 Nov; 27(11):1343-53. PubMed ID: 18670735
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.